Brought to you by 
Recently launched start-up Anthos licenses Novartis' MAA868 anti-thrombotic candidate
01 Mar 2019
Executive Summary
Recently launched Anthos Therapeutics Inc. in-licensed Novartis AG's MAA868, an antibody directed at clotting protein Factors XI and XIa (genetic and pharmacological components of the intrinsic coagulation pathway, which plays a role in hemostasis).
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com